Published in:
01-01-2021 | Sarcopenia | Hepatobiliary Tumors
Moving Toward a More Informed Approach to Risk Stratification of Patients: Comments on Seror et al. CT-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related HCC
Authors:
Susan Tsai, MD, Timothy M. Pawlik, MD, MPH, MTS, PhD
Published in:
Annals of Surgical Oncology
|
Issue 1/2021
Login to get access
Excerpt
Currently, up to 20% of hepatocellular carcinoma (HCC) cases in the Western World may be attributed to nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome.
1 The relative incidence of NAFLD-associated HCC is anticipated to rise as the global obesity and diabetes epidemic worsen; in contrast, viral-associated HCC has decreased with access to effective antiviral treatments. The surgical management of patients with metabolic syndrome-related HCC can be challenging given the increased risk associated with obesity, cardiovascular disease, and diabetes with overall morbidity, as well as underlying liver dysfunction.
2 Although existing nomograms have been utilized to risk stratify surgical patients with varying degrees of success, procedure- and disease-specific tools have not been as developed.
3 Novel tools, therefore, are needed to refine risk estimation among patients being considered for hepatic resection for different indications. …
